• Je něco špatně v tomto záznamu ?

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

ZA. Wainberg, D. Melisi, T. Macarulla, R. Pazo Cid, SR. Chandana, C. De La Fouchardière, A. Dean, I. Kiss, WJ. Lee, TO. Goetze, E. Van Cutsem, AS. Paulson, T. Bekaii-Saab, S. Pant, RA. Hubner, Z. Xiao, H. Chen, F. Benzaghou, EM. O'Reilly

. 2023 ; 402 (10409) : 1272-1281. [pub] 20230911

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001078
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 37708904
DOI 10.1016/s0140-6736(23)01366-1
Knihovny.cz E-zdroje

BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites in 18 countries worldwide across Europe, North America, South America, Asia, and Australia. Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2, administered intravenously, on days 1, 8, and 15 of a 28-day cycle. Balanced block randomisation was stratified by geographical region, performance status, and liver metastases, managed through an interactive web response system. The primary endpoint was overall survival in the intention-to-treat population, evaluated when at least 543 events were observed across the two treatment groups. Safety was evaluated in all patients who received at least one dose of study treatment. This completed trial is registered with ClinicalTrials.gov, NCT04083235. FINDINGS: Between Feb 19, 2020 and Aug 17, 2021, 770 patients were randomly assigned (NALIRIFOX, 383; nab-paclitaxel-gemcitabine, 387; median follow-up 16·1 months [IQR 13·4-19·1]). Median overall survival was 11·1 months (95% CI 10·0-12·1) with NALIRIFOX versus 9·2 months (8·3-10·6) with nab-paclitaxel-gemcitabine (hazard ratio 0·83; 95% CI 0·70-0·99; p=0·036). Grade 3 or higher treatment-emergent adverse events occurred in 322 (87%) of 370 patients receiving NALIRIFOX and 326 (86%) of 379 patients receiving nab-paclitaxel-gemcitabine; treatment-related deaths occurred in six (2%) patients in the NALIRIFOX group and eight (2%) patients in the nab-paclitaxel-gemcitabine group. INTERPRETATION: Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC. FUNDING: Ipsen. TRANSLATION: For the plain language summary see Supplementary Materials section.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001078
003      
CZ-PrNML
005      
20240213093611.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(23)01366-1 $2 doi
035    __
$a (PubMed)37708904
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Wainberg, Zev A $u David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: zwainberg@mednet.ucla.edu
245    10
$a NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial / $c ZA. Wainberg, D. Melisi, T. Macarulla, R. Pazo Cid, SR. Chandana, C. De La Fouchardière, A. Dean, I. Kiss, WJ. Lee, TO. Goetze, E. Van Cutsem, AS. Paulson, T. Bekaii-Saab, S. Pant, RA. Hubner, Z. Xiao, H. Chen, F. Benzaghou, EM. O'Reilly
520    9_
$a BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal malignancies, with few treatment options. NAPOLI 3 aimed to compare the efficacy and safety of NALIRIFOX versus nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: NAPOLI 3 was a randomised, open-label, phase 3 study conducted at 187 community and academic sites in 18 countries worldwide across Europe, North America, South America, Asia, and Australia. Patients with mPDAC and Eastern Cooperative Oncology Group performance status score 0 or 1 were randomly assigned (1:1) to receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle or nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2, administered intravenously, on days 1, 8, and 15 of a 28-day cycle. Balanced block randomisation was stratified by geographical region, performance status, and liver metastases, managed through an interactive web response system. The primary endpoint was overall survival in the intention-to-treat population, evaluated when at least 543 events were observed across the two treatment groups. Safety was evaluated in all patients who received at least one dose of study treatment. This completed trial is registered with ClinicalTrials.gov, NCT04083235. FINDINGS: Between Feb 19, 2020 and Aug 17, 2021, 770 patients were randomly assigned (NALIRIFOX, 383; nab-paclitaxel-gemcitabine, 387; median follow-up 16·1 months [IQR 13·4-19·1]). Median overall survival was 11·1 months (95% CI 10·0-12·1) with NALIRIFOX versus 9·2 months (8·3-10·6) with nab-paclitaxel-gemcitabine (hazard ratio 0·83; 95% CI 0·70-0·99; p=0·036). Grade 3 or higher treatment-emergent adverse events occurred in 322 (87%) of 370 patients receiving NALIRIFOX and 326 (86%) of 379 patients receiving nab-paclitaxel-gemcitabine; treatment-related deaths occurred in six (2%) patients in the NALIRIFOX group and eight (2%) patients in the nab-paclitaxel-gemcitabine group. INTERPRETATION: Our findings support use of the NALIRIFOX regimen as a possible reference regimen for first-line treatment of mPDAC. FUNDING: Ipsen. TRANSLATION: For the plain language summary see Supplementary Materials section.
650    _2
$a lidé $7 D006801
650    _2
$a gemcitabin $7 D000093542
650    _2
$a paclitaxel $7 D017239
650    12
$a nádory slinivky břišní $x farmakoterapie $x patologie $7 D010190
650    _2
$a albuminy $7 D000418
650    12
$a adenokarcinom $x farmakoterapie $7 D000230
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Melisi, Davide $u Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
700    1_
$a Macarulla, Teresa $u Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
700    1_
$a Pazo Cid, Roberto $u Hospital Universitario Miguel Servet, Zaragoza, Spain
700    1_
$a Chandana, Sreenivasa R $u Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA
700    1_
$a De La Fouchardière, Christelle $u Centre Léon Bérard, Lyon, France
700    1_
$a Dean, Andrew $u St John of God Subiaco Hospital, Subiaco, WA, Australia
700    1_
$a Kiss, Igor $u Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Lee, Woo Jin $u National Cancer Center, Goyang, South Korea
700    1_
$a Goetze, Thorsten O $u Krankenhaus Nordwest, Frankfurt am Main, Germany
700    1_
$a Van Cutsem, Eric $u University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium
700    1_
$a Paulson, A Scott $u Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA
700    1_
$a Bekaii-Saab, Tanios $u Mayo Clinic, Scottsdale, AZ, USA
700    1_
$a Pant, Shubham $u MD Anderson Cancer Center, Houston, TX, USA
700    1_
$a Hubner, Richard A $u The Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester, UK
700    1_
$a Xiao, Zhimin $u Ipsen, Cambridge, MA, USA
700    1_
$a Chen, Huanyu $u Ipsen, Cambridge, MA, USA
700    1_
$a Benzaghou, Fawzi $u Ipsen, Cambridge, MA, USA
700    1_
$a O'Reilly, Eileen M $u Memorial Sloan Kettering Cancer Center, New York, NY, USA
773    0_
$w MED00010161 $t Lancet $x 1474-547X $g Roč. 402, č. 10409 (2023), s. 1272-1281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37708904 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093608 $b ABA008
999    __
$a ok $b bmc $g 2049593 $s 1210772
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 402 $c 10409 $d 1272-1281 $e 20230911 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace